Two patients had a confirmed partial response to treatment: one with endometrial adenocarcinoma and phosphoinositide-3-kinase regulatory subunit 2 (PIK3R2)  alteration, and one with ovarian carcinoma and PIK3CA and PTEN alterations. This evidence concerns the gene PIK3R2 and ovarian carcinoma.